Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -105.97% is 12% below its 5-year average of -94.25%, around the middle of its 5-year range (-173.80%–-47.60%).
34.76% below its 12-month average of -78.63%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -22.70%.
RETURN ON ASSETS (ROA)
-105.97%
RETURN ON ASSETS (ROA) AVG TTM
-78.63%
RETURN ON ASSETS (ROA) AVG 3Y
-114.41%
RETURN ON ASSETS (ROA) AVG 5Y
-94.25%
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
-34.76%
CURRENT VS 3Y AVG
+7.38%
CURRENT VS 5Y AVG
-12.44%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-32.27%
median of 862 covered companies
CURRENT VS SECTOR MEDIAN
-228.44%
vs the sector median at left
Vivos Therapeutics, Inc.
Market Cap
$2.14M
Return on Assets (ROA)
-105.97%
TTM Avg
-78.63%
3Y Avg
-114.41%
5Y Avg
-94.25%
Market Cap
$2.13M
Return on Assets (ROA)
-439.95%
TTM Avg
-322.44%
3Y Avg
-242.34%
5Y Avg
-192.54%
Market Cap
$2.32M
Return on Assets (ROA)
-64.42%
TTM Avg
-79.57%
3Y Avg
-65.34%
5Y Avg
-858.61%
Market Cap
$2.37M
Return on Assets (ROA)
-228.77%
TTM Avg
-130.86%
3Y Avg
-126.84%
5Y Avg
-140.90%
Market Cap
$2.37M
Return on Assets (ROA)
-62.07%
TTM Avg
-132.28%
3Y Avg
-89.58%
5Y Avg
-83.72%
Market Cap
$2.38M
Return on Assets (ROA)
-44.98%
TTM Avg
-238.38%
3Y Avg
-161.31%
5Y Avg
-161.69%
Market Cap
$2.38M
Return on Assets (ROA)
-143.82%
TTM Avg
-140.13%
3Y Avg
-102.17%
5Y Avg
-81.19%
Market Cap
$1.88M
Return on Assets (ROA)
-404.67%
TTM Avg
-168.15%
3Y Avg
-182.58%
5Y Avg
-275.93%
Market Cap
$1.88M
Return on Assets (ROA)
-28.33%
TTM Avg
-125.52%
3Y Avg
-210.32%
5Y Avg
-182.20%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Vivos Therapeutics, Inc. (VVOS) | $2.14M | -105.97% | -78.63% | -114.41% | -94.25% |
| GeoVax Labs, Inc. (GOVX)vs › | $2.13M | -439.95% | -322.44% | -242.34% | -192.54% |
| Creative Medical Technology Holdings, Inc. (CELZ)vs › | $2.32M | -64.42% | -79.57% | -65.34% | -858.61% |
| FibroBiologics, Inc. Common Stock (FBLG)vs › | $2.37M | -228.77% | -130.86% | -126.84% | -140.90% |
| Onconetix, Inc. (ONCO)vs › | $2.37M | -62.07% | -132.28% | -89.58% | -83.72% |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH)vs › | $2.38M | -44.98% | -238.38% | -161.31% | -161.69% |
| Moleculin Biotech, Inc. (MBRX)vs › | $2.38M | -143.82% | -140.13% | -102.17% | -81.19% |
| Autonomix Medical, Inc. (AMIX)vs › | $1.88M | -404.67% | -168.15% | -182.58% | -275.93% |
| TransCode Therapeutics, Inc. (RNAZ)vs › | $1.88M | -28.33% | -125.52% | -210.32% | -182.20% |
| Tenon Medical, Inc. (TNON)vs › | $1.84M | -137.72% | -127.80% | -167.94% | -149.58% |
ROA
-106.0%
ROE
N/A
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -84.41% |
| 2024-12-31 | -72.86% |
| 2023-12-31 | -126.59% |
| 2022-12-31 | -173.80% |
| 2021-12-31 | -60.22% |
| 2020-12-31 | -47.60% |
| 2019-12-31 | -142.41% |
| 2018-12-31 | -102.87% |
